

Trikafta[®] (elexacaftor/tezacaftor/ivacaftor; ivacaftor) – Updated label, boxed warning added

- On December 20, 2024, [Vertex announced](#) the **FDA approval of the expanded use of Trikafta (elexacaftor/tezacaftor/ivacaftor; ivacaftor)** for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one *F508del* mutation in the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene or a mutation that is responsive to Trikafta based on clinical and/or *in vitro* data.
 - With this approval, 94 additional non-*F508del* *CFTR* mutations have been added to the Trikafta label. Refer to the drug label for a complete list of responsive mutations.
- In addition to the expanded use approval, the safety information on liver injury and liver failure has been updated from *Warnings and Precautions* to a *Boxed Warning*.
- The label was updated to include data from Trial 5, a randomized, placebo-controlled, double-blind study in 307 patients aged 6 years and older with CF without an *F508del* mutation. Patients were randomized to Trikafta or placebo. The primary endpoint was the absolute change in percent predicted forced expiratory volume in 1 second (ppFEV₁) from baseline through week 24.
 - The treatment difference in absolute change in ppFEV₁ from baseline through week 24 was 9.2 percentage points (95% CI: 7.2, 11.3; p < 0.0001).



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.